Schepmann; Dirk
Patent Applications and Registrations
Patent applications and USPTO patent grants for Schepmann; Dirk.The latest application filed is for "nr2b selective nmda-receptor antagonists for treatment of immune-mediated inflammatory diseases".
- Schepmann; Dirk - Munster DE
| Patent | Date |
|---|---|
| Nr2b Selective Nmda-receptor Antagonists For Treatment Of Immune-mediated Inflammatory Diseases App 20180250308 - Bittner; Stefan ; et al. | 2018-09-06 |
| Perhydroquinoxaline derivatives, their preparation and use in medicaments Grant 8,309,725 - Wunsch , et al. November 13, 2 | 2012-11-13 |
| Perhydroquinoxaline Derivatives App 20100311761 - Wunsch; Bernhard ; et al. | 2010-12-09 |
| Spiro-pyrano-pyrazole Derivatives App 20100197714 - Wunsch; Bernhard ; et al. | 2010-08-05 |
| Spiro [piperidine-4- 4' -thieno [3,2-c] Pyran] Derivatives And Related Compounds As Inhibitors Of The Sigma Receptor For The Treatment Of Psychosis App 20100190813 - Oberdorf; Christoph ; et al. | 2010-07-29 |
| Pyrano-pyrazole-amines App 20100184759 - Wunsch; Bernhard ; et al. | 2010-07-22 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 